^
Association details:
| Biomarker: | KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Ensacove (ensartinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Excerpt:
Patients were aged 18 years or older, had stage IIIb or stage IV ALK-positive NSCLC that had progressed while they were on crizotinib therapy...Alterations that could mediate bypass signalling pathways (n=5)...Ensartinib had poor activity in patients with genetic alterations that could have mediated bypass signalling (eg, mutations in EGFR, KRAS, and PIK3CA)
DOI:
10.1016/S2213-2600(19)30252-8
Trial ID:
